Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study

Young Min Kim, Suk Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae, Myeong Jun Song, Ji Woong Jang, Soon Young Ko, Jae Dong Lee

Clin Mol Hepatol. 2018;24(3):311-318. Published online June 4, 2018

DOI: https://doi.org/10.3350/cmh.2017.0070

View: 8053 Download: 204 Web of Science: 11 Crossref: 11

Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study

Byeong Wook Cho, Seok Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae

Clin Mol Hepatol. 2017;23(1):51-56. Published online March 16, 2017

DOI: https://doi.org/10.3350/cmh.2016.0053

View: 8239 Download: 213 Web of Science: 12 Crossref: 14

Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease

Young Seok Kim, Eun Sun Jung, Wonhee Hur, Si Hyun Bae, Jong Young Choi, Myeong Jun Song, Chang Wook Kim, Se Hyun Jo, Chang Don Lee, Young Sok Lee, Sang Wook Choi, Jin Mo Yang, Jeong Won Jang, Sang Gyune Kim, Seung Won Jung, Hee Kyung Kim, Hee Bok Chae, Seung Kew Yoon

Clin Mol Hepatol. 2013;19(2):120-130. Published online June 27, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.2.120

View: 11076 Download: 89 Crossref: 24

High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B

Hee Bok Chae, Mee Jin Kim, Eui Geun Seo, Yong Hyeok Choi, Hee Seung Lee, Joung Ho Han, Soon Man Yoon, Seon Mee Park, Sei Jin Youn

Clin Mol Hepatol. 2012;18(1):75-83. Published online March 22, 2012

DOI: https://doi.org/10.3350/kjhep.2012.18.1.75

View: 7603 Download: 45 Crossref: 12

1 |

Viewed By 4933	MAFLD: How is it different from NAFLD?
Viewed By 4828	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4727	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4445	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4402	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 214	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 117	MAFLD: How is it different from NAFLD?
Cited By 94	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search